Breaking News, Collaborations & Alliances

Hikma Partners with Emergent for the Sale of KLOXXADO in the U.S. & Canada

Emergent will add KLOXXADO Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.

Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, has entered an exclusive commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone HCl nasal spray 8 mg in the U.S. and Canada.

KLOXXADO was approved by the US Food and Drug Administration (FDA) in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.  Emergent distributes NARCAN Nasal Spray 4 mg, which is the first FDA-approved over-the-counter naloxone product for the emergency treatment of opioid overdose.

Under the terms of the six-year agreement, Emergent will add KLOXXADO Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.  Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner.

“We are thrilled to be partnering with Emergent, who have deep experience in getting lifesaving naloxone nasal spray into the hands of those who can use it to help save lives,” said Hafrun Fridriksdottir, President of Hikma’s Generics business.  “This partnership combines Hikma’s excellent nasal spray manufacturing capabilities with Emergent’s well-established naloxone HCl nasal spray commercial expertise and strong stakeholder engagement.  Hikma remains committed to ensuring that all forms of naloxone we produce—KLOXXADO Nasal Spray, as well as the injectable vials and prefilled syringes that we will continue to manufacture and market—are widely accessible to all who can benefit from them, including patients, friends, family members and the public health community.”

Related Insights

Learn more about Nasal Drug Delivery.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters